There are specific treatment options patients may qualify for depending on the cytogenetic or molecular abnormality detected.
Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
Advertisement
Articles by Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
Advertisement
Latest Updated Articles
Utilizing Pharmacogenomics Information to Guide AML TreatmentPublished: March 3rd 2021 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Environmental Factors Could Influence Type 1 Diabetes Risk in Children Through Epigenetic Changes
3
Less Common Pneumococcal Serotypes Cause More Severe Community-Acquired Pneumonia
4
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
5
